Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioTTT001 in Recurrent/Progressive NSCLC with Meningeal Metastasis
NCT07264569Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BioTTT001 in non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LMD), sponsored by Henan Cancer Hospital. Primary endpoints: Dose-Limiting Toxicity, Maximum Tolerated Dose, and Recommended Phase 2 Dose and Phase Ib dose-escalation study safety at 28 days. Started Jun 2025; status: recruiting.
02
Drugs
BioTTT001
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LMD)
Beyond the preview
Go deeper on NCT07264569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07264569.